![Edwin de Graaf](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Edwin de Graaf
Fondateur chez
Gilde Healthcare Partners BV
Profil
Edwin William de Graaf is the founder of Gilde Healthcare Partners BV, serving as Managing Partner since 2006.
Current jobs include Co-Managing Director at Gilde Healthcare Holding BV, Director at Sanifit Therapeutics SA, Director at Tagworks Pharmaceuticals BV, and Member-Supervisory Board at AM-Pharma Holding BV.
Former jobs include Investment Director at Gilde Investment Management BV from 1998 to 2006, Director at Roche Innovation Center Copenhagen A, Director at Amsterdam Molecular Therapeutics (AMT) Holding NV, Non-Executive Director at Prosonix Ltd., Director at Ascendis Pharma A, Member-Supervisory Board at Pieris AG, Member-Supervisory Board at AM-Pharma BV, and Member-Supervisory Board at uniQure NV.
Education includes a graduate degree from Erasmus University Rotterdam, conferred in 1997, and an undergraduate degree from Amsterdam University of Applied Sciences, conferred in 1991.
Postes actifs de Edwin de Graaf
| Sociétés | Poste | Début |
|---|---|---|
Gilde Healthcare Partners BV
 Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners invests in lower middle market companies located in North America and Europe with an EBITDA of EUR 3 -20 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed, early, later, buyout and growth stage capital requirements with an investment size of EUR 50 million. It takes both minority and majority positions. | Fondateur | 01/07/2006 |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology Engages in financial investment and shareholding activities | Directeur/Membre du Conseil | - |
Gilde Healthcare Holding BV
 Gilde Healthcare Holding BV Financial ConglomeratesFinance Operates as a healthcare investor | Directeur Général | - |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops pharmaceuticals for calcification disorders | Directeur/Membre du Conseil | - |
Tagworks Pharmaceuticals BV
 Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Develops biotechnology | Directeur/Membre du Conseil | - |
Anciens postes connus de Edwin de Graaf
| Sociétés | Poste | Fin |
|---|---|---|
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Directeur/Membre du Conseil | 02/09/2014 |
| UNIQURE N.V. | Directeur/Membre du Conseil | 08/11/2013 |
Gilde Investment Management BV
 Gilde Investment Management BV Investment ManagersFinance GIM investment strategy focuses primarily on transactions involving business succession, buyouts and the growth of innovative firms. GIM provides their investee firms with access to their regional and international network of entrepreneurs, sector experts and advisors. The Gilde Buy Out Fund invests in mid-market private equity with a geographical focus on buyout transactions in Germany, Switzerland, Austria, France, Belgium and Luxembourg. They define mid-market as firms having an enterprise value between €75 and €600 million. They seek investment opportunities across all sectors in non-core businesses spun off from large multinationals, public-to-private transactions, secondary buyouts and family businesses. The Gilde Benelux fund targets only management buyouts of mid-market firms headquartered in the Benelux with transactions typically ranging between €15 and €75 million. They seek firms across all sectors with strong or niche market positions, sustainable cash flows, and growth opportunities through buy and build strategies and entrepreneurial management teams. The Gilde Healthcare fund focuses on private start-up firms in the healthcare sector. They seek primarily European and some US firms that develop new therapeutics, diagnostics and medical devices. They are active investment partners with involvement at board level. Portfolio risk is diversified across different development stages, varying business models, markets and geographies. Their preferred exit route is through IPOs within a realistic time-frame. | Private Equity Investor | 01/07/2006 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology Provides biopharmaceutical products | Directeur/Membre du Conseil | - |
| ░░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Edwin de Graaf
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
87
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Gilde Investment Management BV
Gilde Investment Management BV Investment ManagersFinance GIM investment strategy focuses primarily on transactions involving business succession, buyouts and the growth of innovative firms. GIM provides their investee firms with access to their regional and international network of entrepreneurs, sector experts and advisors. The Gilde Buy Out Fund invests in mid-market private equity with a geographical focus on buyout transactions in Germany, Switzerland, Austria, France, Belgium and Luxembourg. They define mid-market as firms having an enterprise value between €75 and €600 million. They seek investment opportunities across all sectors in non-core businesses spun off from large multinationals, public-to-private transactions, secondary buyouts and family businesses. The Gilde Benelux fund targets only management buyouts of mid-market firms headquartered in the Benelux with transactions typically ranging between €15 and €75 million. They seek firms across all sectors with strong or niche market positions, sustainable cash flows, and growth opportunities through buy and build strategies and entrepreneurial management teams. The Gilde Healthcare fund focuses on private start-up firms in the healthcare sector. They seek primarily European and some US firms that develop new therapeutics, diagnostics and medical devices. They are active investment partners with involvement at board level. Portfolio risk is diversified across different development stages, varying business models, markets and geographies. Their preferred exit route is through IPOs within a realistic time-frame. | Finance |
Pieris AG
 Pieris AG BiotechnologyHealth Technology Develops and markets an Anticalin-brand protein technology | Health Technology |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Health Technology |
Erasmus University Rotterdam
 Erasmus University Rotterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology Engages in financial investment and shareholding activities | Health Technology |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Specializes in human gene therapy for metabolic disorders and ocular diseases | Commercial Services |
Prosonix Ltd.
 Prosonix Ltd. Pharmaceuticals: MajorHealth Technology Develops a portfolio of inhaled respiratory medicines | Health Technology |
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners invests in lower middle market companies located in North America and Europe with an EBITDA of EUR 3 -20 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed, early, later, buyout and growth stage capital requirements with an investment size of EUR 50 million. It takes both minority and majority positions. | Finance |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology Provides biopharmaceutical products | Health Technology |
Gilde Healthcare Holding BV
Gilde Healthcare Holding BV Financial ConglomeratesFinance Operates as a healthcare investor | Finance |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops pharmaceuticals for calcification disorders | Health Technology |
uniQure NV
 uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
Amsterdam University of Applied Sciences
 Amsterdam University of Applied Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tagworks Pharmaceuticals BV
Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Develops biotechnology | Health Technology |
